What's new? Log in Free sign up

Aurinia Pharmaceuticals (AUPH) News and press releases

Company Profile

News

From Benzinga Pro

Aurinia Pharmaceuticals's Return On Capital Employed Insights

What's Going On With Aurinia Pharmaceuticals Stock Today?

Earnings, News, Small Cap, Movers

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig

Aurinia Pharmaceuticals Q4 EPS $(0.18) Beats $(0.27) Estimate, Sales $28.43M Beat $27.78M Estimate

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 28 percent increase over losses of $(0.25) per share

Earnings Scheduled For February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Preview: Aurinia Pharmaceuticals's Earnings

RBC Capital Reiterates Outperform on Aurinia Pharmaceuticals, Maintains $11 Price Target

News, Price Target, Reiteration, Analyst Ratings

RBC Capital analyst Douglas Miehm reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and maintains $11 price target.

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals

Analyst Ratings

RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $11

News, Price Target, Analyst Ratings

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price target from $10 to $11.

Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today

News, Small Cap, Top Stories, Markets, Tech

Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments.

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Press releases

From Benzinga Pro

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune, kidney and rare diseases, announced that the

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

$28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents, and investments of $389.4

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company's

Aurinia Announces PTAB Has Terminated Inter Partes Review

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States' Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had

Thinking about buying stock in First Wave BioPharma, GasLog Partners, Canoo, Aurinia Pharmaceuticals, or Rocket Lab USA?

Opinion, Press Releases

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FWBI, GLOP, GOEV, AUPH, and RKLB.

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million Preliminary unaudited net product revenue for the fourth quarter and full year 2022 of

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company's

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

- Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 - Parties have settled the patent infringement claim against Sun's CEQUA® product -

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.